Gallium
Ganite (gallium) is a small molecule pharmaceutical. Gallium was first approved as Ganite on 1991-01-17. It is used to treat positron-emission tomography in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
Gallium ga, Gallium ga 68 edotreotide, Gallium ga 68 gozetotide, Gozellix, Illuccix, Locametz, Netspot (discontinued: Gallium ga, Ganite, Neoscan)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Gallium nitrate
Gallium citrate ga-67
Gallium ga-68 gozetotide
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| LOCAMETZ | Novartis | N-215841 RX | 2022-03-23 | 1 products, RLD, RS |
| ILLUCCIX | Telix | N-214032 RX | 2021-12-17 | 1 products, RLD, RS |
| GOZELLIX | Telix | N-219592 RX | 2025-03-20 | 1 products, RLD, RS |
| GALLIUM GA 68 GOZETOTIDE | UCLA | N-212642 RX | 2020-12-01 | 1 products, RLD, RS |
| GALLIUM GA 68 GOZETOTIDE | UCSF | N-212643 RX | 2020-12-01 | 1 products, RLD, RS |
Gallium dotatate ga-68
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| NETSPOT | Advanced Accelerator Applications | N-208547 RX | 2016-06-01 | 1 products, RLD, RS |
Gallium ga-68 edotreotide
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| GALLIUM GA 68 EDOTREOTIDE | University of Iowa | N-210828 RX | 2019-08-21 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| ga-68-dotatoc | New Drug Application | 2021-12-08 |
| gallium citrate ga-67 | New Drug Application | 2025-08-13 |
| gallium ga-68 psma-11 | New Drug Application | 2025-01-01 |
| ganite | New Drug Application | 2012-03-19 |
| illuccix | New Drug Application | 2025-06-05 |
| locametz | New Drug Application | 2025-07-03 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| positron-emission tomography | — | D049268 | — |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
V: Various drug classes in atc
— V09: Diagnostic radiopharmaceuticals
— V09H: Inflammation and infection detection
— V09HX: Other diagnostic radiopharmaceuticals for inflammation and infection detection in atc
— V09HX01: Gallium (67ga) citrate
— V09I: Tumour detection radiopharmaceuticals
— V09IX: Other diagnostic radiopharmaceuticals for tumour detection in atc
— V09IX09: Gallium (68ga) edotreotide
— V09IX14: Gallium (68ga) gozetotide
HCPCS
Code | Description |
|---|---|
| A9556 | Gallium ga-67 citrate, diagnostic, per millicurie |
| A9587 | Gallium ga-68, dotatate, diagnostic, 0.1 millicurie |
| A9593 | Gallium ga-68 psma-11, diagnostic, (ucsf), 1 millicurie |
| A9594 | Gallium ga-68 psma-11, diagnostic, (ucla), 1 millicurie |
| A9596 | Gallium ga-68 gozetotide, diagnostic, (illuccix), 1 millicurie |
| A9800 | Gallium ga-68 gozetotide, diagnostic, (locametz), 1 millicurie |
| C9067 | Gallium ga-68, dotatoc, diagnostic, 0.01 mci |
| J1457 | Injection, gallium nitrate, 1 mg |
Clinical
Clinical Trials
319 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Prostatic neoplasms | D011471 | — | C61 | 1 | 1 | — | — | 1 | 2 |
| Neoplasms | D009369 | — | C80 | 1 | 1 | — | — | — | 1 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neuroendocrine carcinoma | D018278 | — | — | — | — | — | — | 1 | 1 |
| Castration-resistant prostatic neoplasms | D064129 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Gallium |
| INN | gallium (67ga) citrate |
| Description | Ganite (gallium) is a small molecule pharmaceutical. Gallium was first approved as Ganite on 1991-01-17. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 7440-55-3 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1201200 |
| ChEBI ID | 49631 |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | 4LJK511Z86 (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 34,087 documents
View more details
Safety
Black-box Warning
Black-box warning for: Ganite
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
436 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use